RxDoctor Payments Data

Geru Wu, MD

Cardiovascular Disease · Cypress, TXNPI 1801153556

Payments from drug & device makers

$1,393in general payments, 2019–2025

Across 46 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$213
  • Boston Scientific$194
  • Amgen$181
  • Abiomed$154
  • AstraZeneca$151
  • Cardiovascular Systems Inc.$135
  • plus $366 from 8 others

What the payments were for

  • Food & beverage$1,35597%
  • Education$383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,393 in reported general payments places this provider in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$161,479
Medicare patients
440
Services billed
1,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$170,197
EntrestoSacubitril/Valsartan34$36,069
JardianceEmpagliflozin33$34,149
Repatha SureclickEvolocumab37$31,815
FarxigaDapagliflozin Propanediol25$29,201
XareltoRivaroxaban24$26,563
BrilintaTicagrelor13$16,785
Metoprolol Succinate408$7,013
Praluent PenAlirocumab11$6,388
Prasugrel Hcl39$4,247
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,323
Atorvastatin Calcium257$2,164
Losartan Potassium206$1,977
Valsartan44$1,911
ClopidogrelClopidogrel Bisulfate135$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$151$45,98638 claims
NovartisEntresto$41$36,06934 claims
Boehringer IngelheimJardiance$105$34,14933 claims
Johnson & JohnsonXarelto$56$26,56324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →